Crystalvue Medical Co Ltd(TW:6527)
NT$72.90-1.30 (-1.75%)
TW:6527
Crystalvue Medical Co Ltd financials statements
NT$72.90
At close:-1.30 (-1.75%)
Crystalvue Medical Co Ltd (6527) Ratios
Crystalvue Medical Co Ltd Ratios
TW:6527's free cash flow for Q2 2026 was NT$-54.43M. For the 2026 fiscal year, TW:6527's free cash flow was decreased by NT$-30.60M and operating cash flow was NT$-23.83M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.45 | 3.00 | 3.46 | 2.90 | 2.75 |
| Quick Ratio | 1.48 | 1.89 | 2.03 | 1.68 | 1.71 |
| Cash Ratio | 0.51 | 1.04 | 1.36 | 0.84 | 1.03 |
| Solvency Ratio | 0.62 | 0.64 | 0.60 | 0.59 | 0.54 |
| Operating Cash Flow Ratio | 0.53 | 0.66 | 0.76 | 0.25 | 0.34 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ 374.13M | NT$ 453.47M | NT$ 474.76M | NT$ 372.31M | NT$ 298.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.02 | 0.02 | 0.03 | 0.04 |
| Debt-to-Equity Ratio | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
| Debt-to-Capital Ratio | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.26 | 1.26 | 1.26 | 1.31 | 1.31 |
| Debt Service Coverage Ratio | 368.06 | 248.62 | 163.07 | 142.46 | 101.61 |
| Interest Coverage Ratio | 399.44 | 229.44 | 143.86 | 143.72 | 93.99 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.48 | 0.75 | 1.03 | 1.29 | 1.55 |
| Net Debt to EBITDA | -0.61 | -1.18 | -1.66 | -0.86 | -1.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 34.97% | 34.46% | 32.37% | 32.90% | 29.29% |
| EBIT Margin | 19.07% | 18.43% | 14.63% | 18.03% | 15.29% |
| EBITDA Margin | 20.94% | 21.81% | 18.17% | 21.32% | 20.96% |
| Operating Profit Margin | 19.07% | 16.71% | 14.28% | 18.03% | 15.29% |
| Pretax Profit Margin | 18.86% | 18.36% | 14.53% | 17.91% | 15.13% |
| Net Profit Margin | 15.49% | 14.65% | 12.55% | 14.46% | 10.70% |
| Continuous Operations Profit Margin | 15.49% | 14.65% | 12.55% | 14.46% | 10.70% |
| Net Income Per EBT | 82.11% | 79.78% | 86.35% | 80.76% | 70.75% |
| EBT Per EBIT | 98.93% | 109.91% | 101.75% | 99.30% | 98.94% |
| Return on Assets (ROA) | 11.35% | 10.73% | 9.59% | 11.36% | 8.23% |
| Return on Equity (ROE) | 14.29% | 13.55% | 12.06% | 14.83% | 10.74% |
| Return on Capital Employed (ROCE) | 17.50% | 15.24% | 13.42% | 17.86% | 14.71% |
| Return on Invested Capital (ROIC) | 14.27% | 12.07% | 11.51% | 14.31% | 10.32% |
| Return on Tangible Assets | 11.37% | 10.77% | 9.63% | 11.37% | 8.24% |
| Earnings Yield | 7.62% | 5.92% | 4.76% | 9.27% | 6.75% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.89 | 4.64 | 6.63 | 0.00 | 0.00 |
| Payables Turnover | 6.87 | 6.30 | 8.05 | 7.76 | 9.78 |
| Inventory Turnover | 2.43 | 2.19 | 1.95 | 2.08 | 2.61 |
| Fixed Asset Turnover | 1.49 | 1.85 | 2.25 | 2.04 | 1.77 |
| Asset Turnover | 0.73 | 0.73 | 0.76 | 0.79 | 0.77 |
| Working Capital Turnover Ratio | 2.24 | 1.81 | 1.84 | 2.18 | 1.64 |
| Cash Conversion Cycle | 190.72 | 187.64 | 197.18 | 128.74 | 102.75 |
| Days of Sales Outstanding | 93.82 | 78.67 | 55.04 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 150.03 | 166.88 | 187.47 | 175.76 | 140.09 |
| Days of Payables Outstanding | 53.14 | 57.91 | 45.33 | 47.02 | 37.34 |
| Operating Cycle | 243.86 | 245.55 | 242.51 | 175.76 | 140.09 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.49 | 6.05 | 6.15 | 2.07 | 2.52 |
| Free Cash Flow Per Share | -1.82 | 0.83 | 5.81 | 1.71 | -11.52 |
| Dividend Paid and CapEx Coverage Ratio | 0.57 | 0.83 | 2.36 | 0.94 | 0.16 |
| Capital Expenditure Coverage Ratio | 0.75 | 1.16 | 18.03 | 5.75 | 0.18 |
| Operating Cash Flow Coverage Ratio | 11.89 | 8.29 | 6.15 | 1.65 | 1.68 |
| Operating Cash Flow to Sales Ratio | 0.15 | 0.18 | 0.19 | 0.07 | 0.09 |
| Free Cash Flow Yield | -2.39% | 0.98% | 6.70% | 3.45% | -25.23% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 13.12 | 16.95 | 20.99 | 10.79 | 14.78 |
| Price-to-Sales (P/S) Ratio | 2.03 | 2.48 | 2.63 | 1.56 | 1.59 |
| Price-to-Book (P/B) Ratio | 1.88 | 2.29 | 2.53 | 1.60 | 1.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -41.87 | 102.25 | 14.92 | 29.01 | -3.96 |
| Price-to-Operating Cash Flow Ratio | 13.86 | 14.04 | 14.09 | 23.96 | 18.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.83 | 0.80 | -2.09 | 0.22 | 0.38 |
| Enterprise Value Multiple | 9.10 | 10.17 | 12.84 | 6.46 | 6.53 |
| Enterprise Value | 1.81B | 1.93B | 1.92B | 1.10B | 988.20M |
| EV to EBITDA | 9.10 | 10.17 | 12.84 | 6.46 | 6.53 |
| EV to Sales | 1.91 | 2.22 | 2.33 | 1.38 | 1.37 |
| EV to Free Cash Flow | -39.26 | 91.63 | 13.21 | 25.61 | -3.42 |
| EV to Operating Cash Flow | 13.00 | 12.58 | 12.48 | 21.16 | 15.62 |
| Tangible Book Value Per Share | 40.48 | 36.93 | 34.04 | 30.97 | 28.69 |
| Shareholders’ Equity Per Share | 40.59 | 37.09 | 34.23 | 30.97 | 28.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.20 | 0.14 | 0.19 | 0.29 |
| Revenue Per Share | 37.45 | 34.30 | 32.91 | 31.76 | 28.80 |
| Net Income Per Share | 5.80 | 5.02 | 4.13 | 4.59 | 3.08 |
| Tax Burden | 0.82 | 0.80 | 0.86 | 0.81 | 0.71 |
| Interest Burden | 0.99 | 1.00 | 0.99 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.05 | 0.06 | 0.07 |
| SG&A to Revenue | 0.11 | 0.12 | 0.13 | 0.11 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Income Quality | 0.78 | 0.96 | 1.29 | 0.36 | 0.58 |
Currency in TWD
